CONMED (CNMD) vs Stereotaxis (STXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
CONMED (CNMD) has outperformed Stereotaxis (STXS) over the past year, losing 3.0% versus a loss of 68.9%. Over five years, CNMD leads with a -68.2% price change compared with -81.3% for STXS. CONMED is the larger company by market cap ($1.33 billion vs $111.2 million), about 12.0 times the size.
CONMED pays a dividend yielding 0.45%, while Stereotaxis does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNMD | STXS |
|---|---|---|
| Share price | $44.42 | $1.11 |
| Market cap | $1.33B | $111.22M |
| 1-day change | -1.53% | 0.00% |
| YTD return | +11.11% | -51.74% |
| 1-year return | -3.03% | -68.91% |
| 5-year return | -68.24% | -81.28% |
| P/E ratio (TTM) | 24.01 | — |
| Forward P/E | 9.29 | — |
| EPS (TTM) | $1.85 | $-0.24 |
| Dividend yield | 0.45% | 0.00% |
| Annual dividend | $0.20 | $0.00 |
| 52-week high | $53.66 | $3.42 |
| 52-week low | $31.44 | $1.09 |
| Distance from 52-week high | -17.22% | -67.54% |
| Analyst consensus | none | none |
| Avg. price target upside | +2.43% | +170.27% |
| Average volume | 482.58K | 808.41K |
| Shares outstanding | 29.95M | 100.20M |
| Employees | 3,900 | 131 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CONMED is about 12.0 times larger than Stereotaxis by market value ($1.33B vs $111.22M).
- CNMD has outperformed STXS by 65.9 percentage points over the past year.
About CONMED
CNMD stock →CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as supporting products include powered resection instruments , fluid management, and visualization systems and the related single-use products that enable surgeons to perform minimally invasive sports medicine surgeries.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 3,900 employees
About Stereotaxis
STXS stock →Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 131 employees
CNMD vs STXS FAQ
Which is bigger, CONMED or Stereotaxis?
CONMED (CNMD) is larger, with a market capitalization of $1.33B compared with $111.22M for Stereotaxis (STXS).
Which stock has performed better over the past year, CNMD or STXS?
CNMD returned -3.03% over the past 12 months, compared with -68.91% for STXS (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, CONMED or Stereotaxis?
CONMED pays a dividend yielding 0.45%, while Stereotaxis does not currently pay a regular dividend.
Are CONMED and Stereotaxis in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.